NASDAQ:VTYX • US92332V1070
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VENTYX BIOSCIENCES INC (VTYX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-08 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2026-01-08 | UBS | Downgrade | Buy -> Neutral |
| 2026-01-08 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2026-01-08 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2026-01-08 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2026-01-08 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-11-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-11-05 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-10-01 | Clear Street | Initiate | Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-08 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-10-15 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-23 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-08-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-07-30 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-13 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-12 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 94.07% | N/A 72.84% | N/A 93.03% | N/A 87.82% | N/A 28.99% | |||||||
| EBITDA YoY % growth | -4.18M | -7.05M -68.66% | -67.12M -852.06% | -113.02M -68.38% | -207.536M -83.63% | -148.184M 28.60% | N/A 24.92% | N/A -9.82% | N/A -8.77% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.18M | -7.05M -68.66% | -67.15M -852.48% | -113.14M -68.49% | -207.694M -83.57% | -148.45M 28.52% | N/A 19.78% | N/A -34.69% | N/A -8.35% | N/A 39.84% | N/A 16.67% | N/A 116.67% | N/A 2,056.81% | N/A 139.41% | N/A 37.10% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.05 73.27% | -3.30 -60.98% | -1.98 40.00% | N/A 25.50% | N/A -17.89% | N/A -10.36% | N/A 46.68% | N/A 22.26% | N/A 84.62% | N/A 1,494.42% | N/A 158.77% | N/A 32.91% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 8.88% | -0.42 -7.23% | -0.44 -16.31% | -0.47 -48.22% | -0.46 -23.65% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -32.592M -0.54% | -34.023M -13.04% | -36.051M -22.90% | -38.87M -56.27% | -41.272M -26.63% |
All data in USD
15 analysts have analysed VTYX and the average price target is 13.64 USD. This implies a price decrease of -2.55% is expected in the next year compared to the current price of 14.
VENTYX BIOSCIENCES INC (VTYX) will report earnings on 2026-03-19, after the market close.
The consensus EPS estimate for the next earnings of VENTYX BIOSCIENCES INC (VTYX) is -0.37 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering VENTYX BIOSCIENCES INC (VTYX) is 15.